Drugs / sIL-4R
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001909 | May 1999 → May 2000 | asthma, hypersensitivity reaction disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sIL-4R | “Soluble recombinantly produced IL-4R (sIL-4R) has been shown to bind and inactivate IL-4, both in vitro and in animal models.” NCT00001909 ↗ |
| Known as | Soluble recombinantly produced IL-4R | “Soluble recombinantly produced IL-4R (sIL-4R) has been shown to bind and inactivate IL-4, both in vitro and in animal models.” NCT00001909 ↗ |
| Action | Inhibit | “bind and inactivate IL-4” NCT00001909 ↗ |
| Modality | Protein / enzyme biologic | “Soluble recombinantly produced IL-4R (sIL-4R) has been shown to bind and inactivate IL-4” NCT00001909 ↗ |
| Route | Inhaled | “Study drug will be delivered via the AERx aerosol drug delivery device.” NCT00001909 ↗ |